New drug aims to treat deadly heart shock
NCT ID NCT07583446
First seen May 14, 2026 · Last updated Jun 21, 2026 · Updated 8 times
Summary
This study tests if the drug istaroxime can help people with mild to moderate cardiogenic shock caused by acute heart failure. About 600 adults will receive either istaroxime or a placebo through an IV for 48 hours. Researchers will check if it improves blood pressure, breathing, and reduces the risk of death or other serious events.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARDIOGENIC SHOCK are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
istaroxime
What this could lead to
If it works, this could provide a new treatment to stabilize blood pressure and reduce complications in people with cardiogenic shock.
What could go wrong
This is an early-to-mid-stage trial with 600 participants. The drug may not improve outcomes or could cause side effects. Results may not apply to all patients.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.